MET Form 144 Notice: 333 Shares to Be Sold on NYSE on 10/01/2025

Rhea-AI Filing Summary

Form 144 notice for MetLife, Inc. (MET) reports a proposed sale of 333 shares of common stock, with an aggregate market value of $27,429.21, intended for sale on 10/01/2025 on the NYSE. The filing lists the securities' original acquisition dates: 114 shares purchased 06/20/2014 and 219 shares purchased 12/19/2014, both bought from GOLDMAN SACHS and paid in cash. The filing also discloses multiple sales of MetLife common stock by MetLife-related accounts during the past three months, including transactions on 07/28/2025, 07/31/2025 and 09/19/2025 with amounts and gross proceeds specified. Certain filer contact and CIK fields appear blank in the provided content.

Positive

• Clear disclosure of the proposed sale quantity (333 shares), aggregate market value ($27,429.21) and planned sale date (10/01/2025).
• Acquisition history provided showing purchase dates (06/20/2014 and 12/19/2014) and cash payment, supporting Rule 144 requirements.
• Past sales listed with dates and gross proceeds, enhancing transparency about recent dispositions by related accounts.

Negative

• Missing filer identification/contact fields (CIK and submission contact details are blank in the provided content).
• Form does not state whether a written trading plan under Rule 10b5-1 exists; the remark section references it but no plan adoption date is provided in the excerpt.

Insights

Securities Compliance Analyst

TL;DR: Routine Rule 144 notice showing a small proposed sale and prior short-term disposals by MetLife accounts; no material undisclosed information apparent.

The filing is procedural and discloses a modest proposed sale of 333 shares valued at $27,429.21 scheduled for 10/01/2025 on the NYSE. Acquisition history is documented with purchase dates in 2014 and cash payment, which supports compliance with Rule 144 holding period and payment disclosure requirements. Multiple recent sales by MetLife-related accounts are listed, which are transparent but not, by themselves, material given the companys large outstanding share count. Missing filer contact/CIK fields should be completed for full regulatory traceability.

Portfolio Risk Analyst

TL;DR: Small issuer-level position and documented prior disposals indicate limited market impact from the proposed sale.

The aggregate 333-share sale represents a negligible fraction of the reported 665,026,054 shares outstanding, implying minimal market impact if executed. The filing records prior sales from several MetLife accounts in July and September 2025 with specified gross proceeds, confirming recent liquidity events. From a portfolio perspective, the amounts disclosed are minor relative to issuer size. The form includes the mandatory representation that the seller has no undisclosed material adverse information, but filer identification fields are incomplete in the provided excerpt.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Wells Fargo 500 W 33rd St New York NY 10001	333	27429.21	665026054	10/01/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	06/20/2014	Purchase	GOLDMAN SACHS			114	06/25/2014	Cash
Common Stock	12/19/2014	Purchase	GOLDMAN SACHS			219	12/24/2014	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Separate Account SPI 1 Metlife Way Whippany NJ 07981	Common Stock	07/28/2025	360	27957.6
MetLife 401k Plan Trust-Large Cap Equity Index 1 Metlife Way Whippany NJ 07981	Common Stock	07/31/2025	209	15873.55
Separate Account II 1 Metlife Way Whippany NJ 07981	Common Stock	09/19/2025	64	5066.24
MetLife 401k Plan Trust-Large Cap Equity Index 1 Metlife Way Whippany NJ 07981	Common Stock	09/19/2025	269	21294.04
Separate Account SPI 1 Metlife Way Whippany NJ 07981	Common Stock	09/19/2025	221	17494.36
Separate Account 149 1 Metlife Way Whippany NJ 07981	Common Stock	09/19/2025	17	1345.72

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does MetLife's (MET) Form 144 report?

The form reports a proposed sale of 333 shares of MetLife common stock valued at $27,429.21, to be sold on 10/01/2025 on the NYSE.

When were the shares to be sold originally acquired?

The shares were acquired in two purchases: 114 shares on 06/20/2014 and 219 shares on 12/19/2014, both purchased from GOLDMAN SACHS and paid in cash.

Are there recent sales of MET stock disclosed in the filing?

Yes. The filing lists multiple sales by MetLife-related accounts in the past three months, including transactions on 07/28/2025, 07/31/2025, and 09/19/2025, with amounts and gross proceeds provided.

On which exchange will the proposed sale occur?

The proposed sale is slated for the New York Stock Exchange (NYSE).

Does the filing include the seller's contact and CIK information?

In the provided content the filer CIK and submission contact fields appear blank or not filled.